Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vanda Pharmaceuticals

4.33
-0.0400-0.92%
Post-market: 4.330.00000.00%16:07 EDT
Volume:506.63K
Turnover:2.20M
Market Cap:252.51M
PE:-13.12
High:4.40
Open:4.34
Low:4.31
Close:4.37
Loading ...

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

PR Newswire
·
07 Apr

Vanda Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Apr

Vanda Pharmaceuticals Seeks US FDA Approval for Bysanti to Treat Schizophrenia, Acute Bipolar I Disorder

MT Newswires Live
·
31 Mar

Vanda Pharmaceuticals Announces the Submission of an Nda to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

THOMSON REUTERS
·
31 Mar

Vanda Pharmaceuticals Inc - Results of Phase Iii Study Expected in 2026

THOMSON REUTERS
·
31 Mar

Vanda Pharmaceuticals Inc - Bysanti Could Be Available in US in 2026

THOMSON REUTERS
·
31 Mar

Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate

MT Newswires Live
·
18 Mar

US High Growth Tech Stocks With Strong Potential

Simply Wall St.
·
01 Mar

February 2025 Penny Stocks To Keep An Eye On

Simply Wall St.
·
27 Feb

Vanda Pharmaceuticals Announces the Publication of an Article Titled "Potential Aso-Based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S"

THOMSON REUTERS
·
24 Feb

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

PR Newswire
·
24 Feb

Vanda Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
18 Feb

Vanda Pharmaceuticals: Promising Revenue Growth and Strategic Pipeline Drive Buy Rating

TIPRANKS
·
18 Feb

Vanda Pharmaceuticals’ Earnings Call: Mixed Results and Future Optimism

TIPRANKS
·
15 Feb

Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges

GuruFocus.com
·
14 Feb

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
14 Feb

Vanda Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Feb

Vanda Pharmaceuticals targets total annual revenue in excess of $1B in 2030

TIPRANKS
·
14 Feb

Vanda Pharmaceuticals reports Q EPS (8c) vs. (4c) last year

TIPRANKS
·
14 Feb

Vanda: Q4 Earnings Snapshot

Associated Press Finance
·
14 Feb